Bin Zhao

发表

Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer.

C. Rudin, C. Faivre-Finn, L. Byers, 2022, Clinical lung cancer.

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

A. Tafreshi, J. Riess, M. Pietanza, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brief Report: Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.

L. Sequist, H. Borghaei, S. Jalal, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Whole‐brain radiotherapy plus sequential or simultaneous integrated boost for the treatment of a limited number of brain metastases in non‐small cell lung cancer: A single‐institution study

Bin Zhao, D. Ma, D. Qing, 2019, Cancer medicine.

Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices

V. Velcheti, Xiaohan Hu, Stephen V. Liu, 2022, Frontiers in Oncology.

Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis.

A. Frederickson, Bin Zhao, A. Arunachalam, 2023, Lung cancer.

Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial

W. Jia, Y. Mu, L. Ji, 2017, Science China Life Sciences.

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.

A. Tafreshi, Ying Cheng, L. Paz-Ares, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status

M. A. Ayers, R. Herbst, Yi-long Wu, 2021, Journal for ImmunoTherapy of Cancer.

Randomized phase III study of first-line pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006.

T. Owonikoko, J. Gray, T. Kato, 2020 .

KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.

A. Chiang, A. Navarro, L. Paz-Ares, 2022, Journal of Clinical Oncology.

Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials

Zhishan Zhang, Qunxiong Pan, Bin Zhao, 2023, EClinicalMedicine.

Clinical Outcomes of PD-1/PD-L1 Inhibitors Among Patients With Advanced or Metastatic Non–Small Cell Lung Cancer With BRAF, ERBB2/HER2, MET, or RET Alterations: A Systematic Literature Review

Bin Zhao, A. Arunachalam, Katherine G Akers, 2023, Journal of immunotherapy.

Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations

M. Pietanza, M. Garassino, H. Aggarwal, 2023, JTO clinical and research reports.